➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Merck
Harvard Business School
Colorcon
Baxter

Last Updated: December 1, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,999,007

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,999,007
Title:Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
Abstract: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.
Inventor(s): Jeffs; Roger (Chapel Hill, NC), Zaccardelli; David (Cary, NC)
Assignee: United Therapeutics Corporation (Silver Spring, MD)
Application Number:12/276,707
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,999,007
Patent Claims: 1. A method of selectively killing gram negative bacteria and inhibiting the growth of gram positive bacteria in a pharmaceutical preparation comprising an active agent selected from the group consisting of treprostinil and treprostinil sodium, the method comprising supplying the active agent with a buffer comprising glycine and having a pH of greater than 10 with low buffer capacity.

2. The method of claim 1, wherein the active agent is treprostinil sodium.

3. The method of claim 1, wherein the buffer further comprises sodium hydroxide.

4. The method of claim 1, wherein the buffer has a pH between about 10 to about 12 with low buffer capacity.

5. The method of claim 4, wherein the buffer has a pH between about 10.2 to about 10.8 with low buffer capacity.

6. The method of claim 1 further inhibiting the growth of fungus, mold, or both.

7. The method of claim 1, wherein the active agent is supplied at a concentration between about 0.001 mg/mL to about 1 mg/mL.

8. The method of claim 2, wherein the treprostinil sodium is supplied at a concentration between about 0.004 mg/mL to about 0.13 mg/mL.

9. The method of claim 1 further comprising injecting the pharmaceutical preparation into a mammal in need thereof.

10. The method of claim 4, wherein the pharmaceutical preparation is injected intravenously into a mammal in need thereof.

11. A method of reducing the occurrence of blood stream infections in a mammal being treated with an active agent comprising administering to the mammal the active agent with a buffer comprising glycine and having a pH of greater than 10, wherein the active agent is selected from the group consisting of treprostinil and treprostinil sodium, and wherein the administration reduces the gram negative bacteria and inhibits the growth of gram positive bacteria.

12. The method of claim 11, wherein the human subject has pulmonary arterial hypertension.

13. The method of claim 11, where in the active agent is administered intravenously.

14. The method of claim 11, wherein the active agent is treprostinil sodium.

15. The method of claim 11, wherein the buffer further comprises sodium hydroxide and has a pH between about 10.2 to about 10.8.

16. The method of claim 11, wherein the buffer has a pH between about 10 to about 12 with low buffer capacity.

17. The method of claim 16, wherein the buffer has a pH between about 10.2 to about 10.8 with low buffer capacity.

18. The method of claim 11 further inhibiting the growth of fungus, mold, or both.

19. The method of claim 11, wherein the active agent is supplied at a concentration between about 0.004 mg/mL to about 0.13 mg/ml.

20. The method of claim 14, wherein the treprostinil sodium is supplied at a concentration between about 0.004 mg/mL to about 0.13 mg/mL.

21. The method of claim 1 wherein the administering is injecting the pharmaceutical preparation into a mammal in need thereof.

22. A pharmaceutical composition comprising an active agent selected from the group consisting of treprostinil and treprostinil sodium in a solution comprising glycine and having a pH greater than 10.

23. The composition of claim 22, wherein the solution further comprises sodium hydroxide.

24. The composition of claim 22, wherein the solution has a pH between about 10 to about 12.

25. The composition of claim 24, wherein the solution has a pH between about 10.2 to about 10.8.

26. The composition of claim 22, wherein the active agent is treprostinil sodium.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
AstraZeneca
Merck
Dow
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.